Navigation Links
European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012
Date:12/4/2011

SEATTLE, Dec. 5, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today an update on the status and progress of its European marketing authorization application ("MAA") for Pixuvri. CTI is seeking a license to market Pixuvri in the E.U. for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") who have failed two or more prior lines of therapy. CTI received the CHMP's day 180 list of outstanding issues, which unlike the day 120 letter, contained only one remaining major objection to CTI's MAA and items not deemed to be major issues. CTI plans on submitting its responses to the day 180 list of outstanding issues by December 19, 2011. If the responses satisfy the outstanding objection and the CHMP does not require an oral explanation a positive recommendation on the approval of Pixuvri could be made at the January 19th meeting of the CHMP.

"We believe we have made excellent progress working collegially with the E.U. rapporteurs on addressing items raised in the day 120 list of outstanding issues because we resolved all major objections other than the one major remaining objection in the day 180 letter," stated James A. Bianco,  M.D, CEO of CTI.

To address the remaining major objection, the CHMP required that CTI provide a literature review of mechanisms of rituximab resistance and analyses that demonstrate the efficacy of Pixuvri in patients with prior rituximab treatment, as well as information to address some additional questions that were not deemed to be major issues and could be addressed by additional analyses of currently available data.

On November 29th CTI met with the rapporteurs and team members from the EMA for a clarification meeting at which CTI and its clinical expert presented the results of its literature review, additional supportive analyses regarding the efficacy of pixantrone across response rates and progression free surviv
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CardioInsight Announces CE Mark Clearance and European Launch of the ECVUE™ Non-Invasive Electrocardiographic Mapping System
2. Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
3. Delcath Announces Agreement With European Institute of Oncology for Initial Launch of Hepatic Chemosat Delivery System in the European Union
4. X-ray Equipment - Top 5 European Markets
5. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
6. RSB Spine, LLC, Announces European Patent Allowance
7. Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
8. Amgen Statement on European Investor Visit
9. European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive)
10. Misonix Announces its Exhibition at the European Association of Neurosurgical Societies
11. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... FDA today took legal action against a dietary supplement ... noting the changes on the final product labels. The ... the U.S. Department of Justice, would stop the defendants ... being in violation of the Federal Food, Drug, and ...
... will be able to share Thanksgiving and other holidays with ... safely and independently in the comfort of their own homes, ... Homecare also provides tremendous value to more than eight ... home, says the American Association for Homecare. Home medical equipment ...
Cached Medicine Technology:FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 2FDA Takes Enforcement Action Against Pennsylvania Dietary Supplement Maker 3The Holidays Highlight the Value of Home-Based Health Care 2The Holidays Highlight the Value of Home-Based Health Care 3
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... momentum slowly but surely as anonymity assists the patient to ... sort, as they do not come face to face with ... is not visible, it is easier for the client to ... treatment for mental or emotional illnesses," explains Fredi Lang of ...
... developed a vaccine for dust mite allergy sufferers.Dust mites ... addition to other things//. They live in bedding, upholstered ... to the feces and body parts left by these ... ,Cytos has claimed that their vaccine has been tested ...
... According to a new study done by Dr. Honglei Chen, ... that long hours of sleep may result in Parkinson’s disease//. ... It said that those who work in the rotating night ... ,This is because the author says that rotating ...
... has caused the health officials to request the airlines ... Disease Control and Prevention have asked them to collect ... contact numbers and detailed flight information, to help track ... an additional expenditure on the airlines which is already ...
... new survey conducted by the American Psychiatric Association shows 44% ... mental illness, its symptoms, causes or the methods of treatment//. ... Americans believed wrongly that an emotional or personal weakness is ... showed that almost about 84% of the people felt that ...
... when taken along with gentamycin can prevent the latter’s ... of the study are especially important in the developing ... includes gentamycin, is commonly used due to their low ... been published in this week's New England Journal of ...
Cached Medicine News:Health News:Anonymity Helps In Overcoming Inhibitions During Online Counseling 2Health News:Aspirin to Prevent Deafness caused by Antibiotics 2
... Confidence…real time , ... cart-based system for permanent, ... ... IOM system. Both configurations ...
... is a high-volume analyzer that builds upon ... AU5200 analyzer and the latest Olympus technological ... chemistry-immuno testing with up to 147 on-board ... per hour. Choose from Olympus 122 test ...
This kit has been designed for the quantitative,determination of total immunoreactive intact PTH (Total,Intact PTH) in blood samples. The Total Intact PTH,level is the sum of PTH (1-84) and N-t...
Microwell EIA for the detection of EPO (Erythropoietin)...
Medicine Products: